Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts

Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells

(2014) Arnim Weber et al.   Translational Oncology

Patient-derived xenografts recapitulate molecular features of human uveal melanomas

(2013) Cécile Laurent et al.   Molecular Oncology

Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1

(2012) Henry Zall et al.   Molecular Cancer

An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737

(2011) S. Al-harbi et al.   BLOOD

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents

(2011) Cyrille Touzeau et al.   CLINICAL CANCER RESEARCH

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

(2011) K. M. Lucas et al.   CLINICAL CANCER RESEARCH

Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

(2011) Nguyen Tan et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1

(2011) C. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

BH3 mimetics activate multiple pro-autophagic pathways

(2011) S A Malik et al.   ONCOGENE

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53

(2011) Steven N. Reuland et al.   PLoS One

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

(2010) Scott Ackler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Molecular Basis of Synergism between Carboplatin and ABT-737 Therapy Targeting Ovarian Carcinomas

(2010) H. V. Jain et al.   CANCER RESEARCH

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines

(2010) H. Xu et al.   CLINICAL CANCER RESEARCH

Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors

(2010) F. Nemati et al.   CLINICAL CANCER RESEARCH

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The Pan-Bcl-2 Inhibitor (-)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma

(2010) V. Voss et al.   MOLECULAR CANCER RESEARCH

Effectiveness of Treatments for Metastatic Uveal Melanoma

(2009) James J. Augsburger et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

(2009) C. N. Sternberg et al.   ANNALS OF ONCOLOGY

Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model

(2009) K. W. Kim et al.   CLINICAL CANCER RESEARCH

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

(2009) Susan O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

(2009) Asher A. Chanan-Khan et al.   LEUKEMIA & LYMPHOMA

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients

(2008) Verena Voelter et al.   MELANOMA RESEARCH